Transplantation for Severe Combined Immunodeficiency With HLA-A,B,D,DR Incompatible Parental Marrow Cells Fractionated by Soybean Agglutinin and Sheep Red Blood Cells

Three patients with severe combined immunodeficiency (SCID) received transplants of HLA haplotype-mismatched parental bone marrow depleted of T lymphocytes by differential agglutination with soybean agglutinin (SBA) and subsequent E-rosette depletion. Two patients achieved durable engraftment with r...

Full description

Saved in:
Bibliographic Details
Published in:Blood 1983-02, Vol.61 (2), p.341-348
Main Authors: Reisner, Yair, Kapoor, Neena, Kirkpatrick, Dahlia, Pollack, Marilyn S., Cunningham–Rundles, Susanna, Dupont, Bo, Hodes, Marquis Z., Good, Robert A., O'Reilly, Richard J.
Format: Article
Language:English
Subjects:
Bone Marrow Transplantation
Child, Preschool
Histocompatibility
Humans
Immunologic Deficiency Syndromes - therapy
Infant
Lectins - immunology
Lymphocyte Culture Test, Mixed
Lymphocyte Depletion
Male
Phenotype
Rosette Formation
T-Lymphocytes - immunology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Three patients with severe combined immunodeficiency (SCID) received transplants of HLA haplotype-mismatched parental bone marrow depleted of T lymphocytes by differential agglutination with soybean agglutinin (SBA) and subsequent E-rosette depletion. Two patients achieved durable engraftment with reconstitution of both humoral and cell-mediated immunity. Neither of these patients developed graft versus host disease (GVHD). The third patient achieved only a transient engraftment with concomitant development of mitogen-responsive lymphocytes of paternal origin. Our experience indicates that depletion of T lymphocytes by this technique can abrogate the potential of histoincompatible marrow grafts to induce lethal GVHD without limiting immunologic reconstitution. It also provides further evidence of nonimmune mechanisms of graft resistance that may necessitate preparative treatment of patients with SCID before transplantation with HLA-mismatched marrow cells.
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V61.2.341.341